EvE Bio’s five-year mission is to actualize a new biomedical discipline: mapping the pharmome. Pharmome mapping identifies all the unintended targets (“off-targets”) of small-molecule pharmaceutical drugs, because no drug is perfect; no drug acts at only its single intended target in the human body. Yet today pharmaceutical developers consider only a relative handful of ‘bad actors’ in their efforts to identify their drugs’ off-targets, leaving the vast extent of the druggable genome mostly unconsidered.